Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...

With JOBEVNE, Biocon Biologics further cements its position in the U.S. oncology biosimilars market, where it already offers OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb).

The approval of JOBEVNE expands Biocon Biologics’ biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also ...

With this approval, Jobevne becomes the company’s fourth oncology biosimilar in the US, adding to its existing portfolio that includes OGIVRI (trastuzumab), FULPHILA (pegfilgrastim), and ABEVMY ...

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today ...

The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average. Supported by world-class markets data from ...

Pfizer and AbbVie shares declined more than 4%, Merck dropped almost 4%, and Eli Lilly pulled back over 3% in early trading. Daily Merck & Company, Inc. Dow pharmaceutical components are leading ...

Dyrupeg is a biosimilar medicine containing the active substance pegfilgrastim, intended to reduce the duration of neutropenia and prevent febrile neutropenia in adult cancer patients treated with ...

More than 200 members of the United Steelworkers Union Local 10-00086 at Merck & Co. rallied outside Building 53 near Gate 1 at the Upper Gwynedd pharmaceutical giant Wednesday afternoon in support of ...

BAGSVAERD, Denmark I March 29, 2025 I Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced ...